Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

NCT01737502 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

NCT03377023 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer

NCT00866528 ·Status: COMPLETED ·Phase: PHASE1

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

NCT02503358 ·Status: COMPLETED ·Phase: PHASE1

Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00094835 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

NCT02950038 ·Status: WITHDRAWN ·Phase: PHASE2

-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer

NCT01441128 ·Status: TERMINATED ·Phase: PHASE1

A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer

NCT00735696 ·Status: COMPLETED ·Phase: PHASE2

Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer

NCT05387109 ·Status: UNKNOWN ·Phase: PHASE4

Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer

NCT02733250 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer

NCT01233687 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00006929 ·Status: COMPLETED ·Phase: PHASE2

A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00555256 ·Status: COMPLETED ·Phase: PHASE1

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

NCT02869789 ·Status: COMPLETED ·Phase: PHASE4

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

NCT04332367 ·Status: RECRUITING ·Phase: PHASE2

Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

NCT00979212 ·Status: COMPLETED ·Phase: PHASE2

Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

NCT00633529 ·Status: COMPLETED ·Phase: PHASE1

PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

NCT05234307 ·Status: RECRUITING ·Phase: PHASE1

A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer

NCT07082179 ·Status: RECRUITING ·Phase: PHASE2

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

NCT02967133 ·Status: TERMINATED ·Phase: PHASE2

Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy

NCT03302247 ·Status: TERMINATED ·Phase: PHASE2

Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

NCT01027598 ·Status: COMPLETED ·Phase: PHASE2

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

NCT06173505 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

NCT06918132 ·Status: RECRUITING ·Phase: PHASE2

An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease

NCT03770299 ·Status: WITHDRAWN ·Phase: PHASE2